News & Updates
Filter by Specialty:
Fluvoxamine strikes out in mild-to-moderate COVID-19
Treatment with fluvoxamine does not appear to improve outcomes in patients with mild-to-moderate COVID-19, with a study showing that the drug does not shorten symptom duration as compared with placebo.
Fluvoxamine strikes out in mild-to-moderate COVID-19
18 Jan 2023
Regdanvimab for COVID-19 effective against Delta variant
The neutralizing antibody regdanvimab appears to be useful in the treatment of mild-to-moderate COVID-19, with a recent study showing that the drug may prevent disease worsening in patients, including those infected with the Delta variant.
Regdanvimab for COVID-19 effective against Delta variant
13 Jan 2023
Lower plasma ACE2 levels may partially mediate COVID-19 risks in overweight/obesity or low socioeconomic position
Lower plasma angiotensin-converting enzyme 2 (ACE2) levels may partially mediate COVID-19 risks in individuals with overweight/obesity or low socioeconomic position (SEP; referring to low educational attainment), according to a large-scale Mendelian randomization study conducted by researchers at the University of Hong Kong (HKU) and the Chinese University of Hong Kong (CUHK).
Lower plasma ACE2 levels may partially mediate COVID-19 risks in overweight/obesity or low socioeconomic position
10 Jan 2023
Cardiovascular death among seniors with pneumonia down with antibiotic therapy
In the treatment of older patients hospitalized with community-acquired pneumonia, the use of guideline-concordant antibiotic therapy significantly lowers the risk of cardiovascular death in the first year of follow-up, as reported in a study.
Cardiovascular death among seniors with pneumonia down with antibiotic therapy
10 Jan 2023
Oseltamivir as good as peramivir in influenza B but yields better outcomes in influenza A
Oseltamivir appears to have similar efficacy as peramivir in the treatment of young children with severe influenza B, a study has found. However, oseltamivir treatment leads to better recovery and shorter hospitalization in children with severe influenza A.
Oseltamivir as good as peramivir in influenza B but yields better outcomes in influenza A
08 Jan 2023
Investigational antisense oligonucleotide for chronic HBV infection shows positive results
Treatment with the antisense oligonucleotide bepirovirsen appears to lead to sustained loss of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA in up to 10 percent of patients with chronic HBV infection, according to the results of the phase IIb study B-Clear.